|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 2 | Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor显示文摘 | Schultz HD Gardner DG Deschepper CF | 1988 | Am J Physiol1988，155，12： | 1 |
| 3 | A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenol 显示文摘 | Schultze AE Main BW Hall DG | 2011 | Toxicol Pathol2011，39，4： | 1 |
| 4 | Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials显示文摘 | Schultz KF Chalmers I Hayes RJ Altman DG | 1995 | JAMA1995，273，： | 1 |
| 5 | Empirical evidence of bias:Dimensions of methodological quality associated with estimates of treatment effects in controlled trials显示文摘 | Schultz KF Chalmers I Hayes RJ Altman DG | 1995 | JAMA1995，273，： | 1 |
| 6 | Further observations on the biology of the sea nettle and jellyfishes in Chesapeake Bay显示文摘 | Cargo DG Schultz LP | | 0，，： | 1 |
| 7 | Outcomes in breast cancer patients relative to margin status after treatment with breastconserving surgery and radiation therapy: the University of Pennsylvania experience显示文摘 | Peterson ME Schultz DG Reynolds C | 1999 | Int J Radiat Oncol Biol Phys1999，43，5： | 1 |
| 8 | Health--related quality of life and health--adjusted life expectancy of people with diabetes in Ontario,Canada, 1996-- 1997显示文摘 | Manuel DG Schultz SE | 2004 | Diabetes Care2004，27，2： | 1 |
| 9 | Co-contraction of lumbar muscles during the development of time-varying triaxial moments显示文摘 | Thelen DG Schultz Ab | 1995 | J Orthop Res1995，13，3： | 1 |
| 10 | Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada,1996-1997显示文摘 | Manuel DG Schultz SE | 2004 | Diabetes Care2004，27，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员